Market Survey on Atherosclerosis Market Covering Sales Outlook, Up-to-date Key Trends, Market Size and Forecast, Per Capita Expenditure, Company Share, Brand Share, Regulations, Reimbursement Scenario, Epidemiology, Procedure Numbers, and Pipeline Assessment
An In-depth Market Insights of Atherosclerosis Market including Atherosclerosis Medications, Cholesterol-lowering Medications, Antiplatelet drugs and Anticoagulants, Atherosclerosis Beta Blockers, Diuretics or Water Pills, and Angiotensin Converting Enzyme (Ace) Inhibitors Covering 30+ Countries like United States, United Kingdom, Germany, France, Norway, Sweden, Saudi Arabia, United Arab Emirates, Japan, Korea, Australia, New Zealand, and Others
The atherosclerosis market is anticipated to attain a valuation of US$ 59,514.3 million by 2033, capturing a CAGR of 2.8% between 2023 and 2033 from a current value of US$ 45,165.6 million in 2023. The rise in the prevalence of cardiovascular disorders is a significant factor driving market growth.
Data Points
Key Statistics
Expected Market Value (2023)
US$ 45,165.6 million
Anticipated Forecast Value (2033)
US$ 59,514.3 million
Projected Growth Rate (2023 to 2033)
2.8% CAGR
Atherosclerosis is the shrinking of a vein caused by plaque accumulation. Atherosclerosis is a kind of arteriosclerosis (stiffening or solidifying of the artery walls). The sickness disrupts the flow of blood throughout the body, posing significant cardiovascular complications.
Atherosclerosis starts when the endothelium is damaged, allowing LDL cholesterol to accumulate in the arterial wall. To clean up the cholesterol, the body sends macrophage white platelets.
However, the cells occasionally halt at the impacted spot. After a while, this resulted in plaque formation, which was composed of bad cholesterol (LDL cholesterol) and macrophage white platelets. The plaque obstructs the corridor, disrupting the flow of blood throughout the body. This may result in blood clusters, which can lead to life-threatening diseases such as heart attack, stroke, and other cardiovascular disorders.
Aside from age, the following factors increase the risk of atherosclerosis: high blood pressure, high cholesterol, diabetes, obesity, smoking or other tobacco use, family history of early heart disease, lack of exercise, and a poor diet.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Atherosclerosis Demand Analysis (2018 to 2022) Vs. Market Outlook (2023 to 2033)
The global demand for atherosclerosis treatment is projected to increase at a CAGR of 2.8% during the forecast period between 2023 and 2033, reaching a total of US$ 59,514.3 million in 2033, according to a report from Future Market Insights (FMI). From 2018 to 2022, sales witnessed significant growth, registering a CAGR of 1.8%.
The rise in heart attacks caused by atherosclerosis or coronary heart disease is expected to drive up demand for atherosclerosis treatment products. The aging population is expected to drive demand during the forecast period.
According to the CDC (Centres for Disease Control and Prevention), coronary illness accounts for approximately 610,000 deaths per year in the United States, accounting for roughly one out of every four reported deaths. Coronary disease is the most well-known type of coronary disease, killing over 370,000 people each year.
This increase in the baby boomer population is expected to increase in atherosclerosis patients and, as a result, demand for treatment over the forecast period.
The market for atherosclerosis is growing due to increased prevalence, obesity, sedentary lifestyle, hypertension, dyslipidemia, particularly a decrease in high thickness cholesterol (HDL-C), and elevated cholesterol slim down.
Statins, angiotensin-converting enzyme (ACE) inhibitors, beta-blockers (BB), antiplatelets, calcium channel blockers (CCBs), and nitrates are among the medications used to treat atherosclerosis.
Yosprala (headache medicine and omeprazole), Praluent (alirocumab), Dalcetrapib (RG1658), Vorapaxar (SCH 530348), Canakinumab (ACZ885), Varespladib (A 002), Aliskiren, Generx, Xarelto (rivaroxaban), Anacetrapib (MK0859), and others are expected to be launched during the forecasting period.
Which are Some Prominent Drivers of the Atherosclerosis Market?
An Expanding Geriatric Population Base and Subsequent Rise in Cardiac Anomalies
The worldwide atherosclerosis industry is poised to increase as the geriatric population grows and the incidence rate of heart attacks caused by coronary heart disease or atherosclerosis rises. Furthermore, the availability of new treatment approaches (both branded and generic) is a key driver of the global atherosclerosis therapeutics market.
According to the Centres for Disease Control and Prevention (CDC), approximately 610 000 people in the United States died as a result of heart disease, accounting for nearly one out of every four deaths. Coronary artery disease is the most common type of heart disease, accounting for around 370,000 deaths each year. These factors are expected to boost the global market for atherosclerosis.
Increasing Prevalence of Obesity and High Cholesterol to Widen Growth Prospects
Rising obesity and high cholesterol rates are expected to boost market growth by increasing the risk of atherosclerosis. According to the World Health Organization, around 40 million children under five were overweight or obese in 2018. (WHO).
Increased consumption of high-fat, high-sugar foods, as well as an increase in physical immobility due to the increasingly inactive nature of many types of work, changing modes of transportation, and increasing urbanization, all contribute to high cholesterol rates, resulting in rapid market growth.
Furthermore, rising awareness-raising initiatives by public and private organizations are expected to expand the atherosclerosis market. Furthermore, the sedentary lifestyle of people, such as high alcohol consumption and smoking addiction, is projected to result in the expansion of the atherosclerosis market. The rising level of disposable income and the high prevalence of high blood pressure are expected to drive the industry's growth rate during the forecast period.
Find your sweet spots for generating winning opportunities in this market.
What Are the Challenges Faced by the Atherosclerosis Market?
Absence of Definitive Therapy to Stymie the Market Growth
New competitors in the atherosclerosis market have demonstrated increased adequacy and security profiles, as well as a reduction in CHD risk factors. Atherosclerosis, also known as coronary artery disease, has two treatment options: coronary artery bypass grafting (CABG) and angioplasty.
The CAD death rate is relatively high when compared to other diseases caused by coronary events associated with CAD, such as myocardial infections (MI), angina, and strokes. As a result, the antidote to such situations remains an unexplored area of research and development for pharmaceutical companies seeking to bring breakthrough drugs to market.
However, the absence of definitive therapy, side effects and limited efficacy of current medications, and reliance on symptom-based treatment in certain situations are likely to hinder revenue growth in the atherosclerosis market throughout the forecast period.
Moreover, the high cost of the treatment is expected to hamper the market's growth rate. The atherosclerosis market is estimated to be challenged by a lack of skilled professionals and a dearth of healthcare infrastructure in developing economies. Furthermore, strict regulatory policies and a lack of public awareness might restrain and impede market growth during the forecast period.
Region-wise Insights
How is the North American Atherosclerosis Market Shaping Up?
High Prevalence of Cardiovascular Diseases Creating Opportunities for Atherosclerosis Treatment Providers
Country
Forecast CAGR % (2023 to 2033)
North America’s Market Share % (2022)
37.8%
The United States Market Share % (2022)
32.4%
The North American atherosclerosis market is slated to acquire a market share of 37.8% in 2022. The presence of key players, the high prevalence of cardiovascular diseases and atherosclerosis, and the established healthcare infrastructure are some key factors responsible for the market's large share. Furthermore, beneficial government initiatives and an increase in the number of research collaborations are expected to drive market growth.
Because of supportive healthcare policies, several patients, and a developed healthcare market, the United States have the largest share in this region. Around 647,000 Americans die annually from heart disease, accounting for one in every four deaths.
Every year, the United States spends around US$ 219 billion on heart disease. According to statistics, this country's increasing patient pool and disposable revenue drive regional market growth.
Why is Asia Pacific considering the Fast-growing Market for Atherosclerosis?
Increasing Geriatric Population Favoring Market Growth
Country
Forecast CAGR % (2023 to 2033)
China
3.9%
India
4.4%
The Asia Pacific is anticipated to increase during the forecast period due to an increasing geriatric population and rising disposable income levels in this region.
Furthermore, the expansion of healthcare infrastructure and rising government initiatives are expected to accelerate the market's growth rate in this region. Thus, the Asia Pacific is expected to hold 25% of the market share for the atherosclerosis market in the forecast period.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need and save 40%!
Category-wise Insights
Which Therapy Segment is Gaining Traction in the Atherosclerosis Market?
Cholesterol-lowering Medications to Remain Most Sought After
Segment
Market Share % (2022)
Cholesterol Lowering Medication
44.7%
Statins and fibrates are examples of cholesterol-lowering medications. The segment's dominance is attributed to the rising prevalence of cardiovascular disease, high cholesterol, and obesity worldwide. According to the World Health Organization, 40 million children under the age of five were overweight or obese in 2018.
A higher intake of energy-dense foods high in fat and sugars, as well as an increase in physical immobility due to the increasingly inactive nature of many types of work, changing modes of transportation, and increasing urbanization, are factors driving high cholesterol rates and, ultimately, boosting segment growth.
In addition, the approval of new cholesterol-lowering medicines is boosting segment growth. For example, the drugs alirocumab (Praluent) and evolocumab (Repatha) belong to a new class of drugs known as PCSK9 inhibitors, which reduce harmful LDL cholesterol levels by more than 50%. Novel treatment drugs of this type boost segment growth. The growing patient pool and increased approvals for new medicines boost segment growth.
Which is the Leading Distribution Channel of the Atherosclerosis Market?
Retail Pharmacies are expected to Continue to Be a Beneficial Distribution Channel
Segment
Market Share % (2022)
Retail Pharmacies
38.2%
As per Future Market Insights (FMI), the retail pharmacies segment is expected to become the primary point-of-sale channel for atherosclerosis as they expand to even the most remote locations, making it easier for consumers to present prescriptions and purchase drugs.
Furthermore, retail pharmacists provide more consultative services regarding drug administration routes and potential side effects. Retail pharmacies carry a variety of brands, making them a good place for patients to shop. Hospital pharmacists, on the other hand, operate in a more clinic-oriented manner, having frequent contact with doctors and nurses, and they manage their inventories with only specific brands.
Start-ups for Atherosclerosis Market
Key startup players in the atherosclerosis market:
Moderna is a leader in the development of a new class of drugs based on messenger RNA (mRNA). This novel drug platform is based on the discovery that modified mRNA can direct the body's cellular machinery to produce nearly any protein of interest, ranging from native proteins to antibodies and completely novel protein constructs with therapeutic activity inside and outside cells.
Humacyte creates novel human tissue-based investigational products for regenerative medicine and vascular surgery. The company's proprietary technology platform is used to isolate and grow stable, ‘off-the-shelf’ investigational human tissue replacements that, if approved, could be tailored to pre-designed clinical and commercial specifications.
CardioDx is a Redwood City, California-based cardiovascular genomic diagnostics company. CardioDx creates clinically validated genomic tests to aid in assessing and tailoring care for people suffering from cardiovascular diseases such as coronary artery disease (CAD), cardiac arrhythmias, and heart failure.
Anthos Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for patients with high-risk cardiovascular disease.
Avinger creates precision medical device technology to combat Peripheral Artery Disease and assist patients in keeping their legs.
Milestone Pharmaceuticals is a pharmaceutical company that develops small-molecule therapeutics for the treatment of cardiovascular diseases.
MyoKardia is a precision medicine company that is discovering, developing, and commercializing targeted therapies for the treatment of serious and underserved rare cardiovascular diseases. Our initial focus is on treating heritable cardiomyopathies, a rare, genetically-driven form of heart failure.
On the basis of their proprietary AFFITOME technology, AFFiRiS develops first-in-class antigen-specific immunotherapies for the prevention and treatment of chronic illnesses. We believe that active immunization can play a significant role in preventing and treating chronic civilization illnesses such as atherosclerosis, diabetes, and neurodegenerative diseases.
Flow MedTech is a Health Wildcatters portfolio company that is developing an innovative therapy to reduce the risk of stroke in atrial fibrillation patients by preventing clot formation in the left atrial appendage. The company's goal is to design, develop, and commercialize novel catheter-based devices to reduce the risk of stroke.
Market Competition
The market for atherosclerosis is moderately competitive, with several key players. Some companies that are currently dominating the market are as follows GlaxoSmithKline Plc., Merck & Co., Inc., F. Hoffmann-La Roche Ltd., Isis, Pharmaceuticals, Inc., Anthera Pharmaceuticals, Novartis AG, Sanofi, Johnson and Johnson, Bayer AG, The Medicine Company and Cardium Therapeutics are some prominent players.
Recent Developments in the Atherosclerosis Market Are
In August 2022, AstraZeneca and Merck, known as MSD outside the United States and Canada, announced that the European Commission (EC) has approved LYNPARZA as monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline BRCA1/2 mutations (gBRCAm) and HER2-negative high-risk early breast cancer who have previously received neoadjuvant or adjuvant chemotherapy.
In July 2022, GSK plc announced that its wholly owned subsidiary, GSK Finance (No.3) plc, is expected to repurchase all its outstanding Exchangeable Senior Notes due 2023 for cash.
In June 2022, Novartis announced new data from the Phase 3 ASCLEPIOS I/II trials and the ALITHIOS open-label extension demonstrating that continuous Kesimpta® (ofatumumab) treatment significantly increased the odds of achieving no evidence of disease activity (NEDA-3) versus switching from teriflunomide. These findings were presented at the European Academy of Neurology (EAN) Annual Meeting, which is going to be held virtually on June 25-28, 2022, in Vienna, Austria.
Report Scope
Report Attribute
Details
Market Value in 2023
US$ 45,165.6 million
Market Value in 2033
US$ 59,514.3 million
Growth Rate
CAGR of 2.8% from 2023 to 2033
Base Year for Estimation
2022
Historical Data
2018 to 2022
Forecast Period
2023 to 2033
Quantitative Units
Revenue in US$ million and CAGR from 2023 to 2033
Report Coverage
Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis
Segments Covered
Therapy
Surgery
Distribution Channel
Region
Regions Covered
North America
Latin America
Europe
Asia Pacific
The Middle East and Africa
Key Countries Profiled
The United States
Canada
Brazil
Mexico
Germany
The United Kingdom
France
Spain
Italy
China
Japan
South Korea
GCC
South Africa
Israel
Key Companies Profiled
GlaxoSmithKline plc.
Merck & Co., Inc.
F. Hoffmann-La Roche Ltd.
Isis Pharmaceuticals, Inc.
Anthera Pharmaceuticals
Novartis AG
Sanofi
Johnson and Johnson
Bayer AG
The Medicine Company
Cardium Therapeutics
Customization
Available Upon Request
Key Segments Profiled in the Atherosclerosis Industry Survey
By Therapy:
Atherosclerosis Medications
Cholesterol-lowering Medications
Antiplatelet drugs and Anticoagulants
Atherosclerosis Beta Blockers
Diuretics or Water Pills
Angiotensin Converting Enzyme (Ace) Inhibitors
Other Atherosclerosis Treatment Therapies
By Surgery:
Bypass Surgery (Coronary Artery Bypass Grafting (CABG))
Angioplasty
Atherectomy
By Distribution Channel:
Hospitals
Pharmacies
Drug Stores
Retail Pharmacies
Clinics
By Region:
North America
Latin America
Europe
Asia Pacific
The Middle East and Africa
Frequently Asked Questions
What is Driving Demand in Asia Pacific?
An increasing geriatric population drives the Asia Pacific market.
What Drives Sales of Atherosclerosis?
The increasing prevalence of obesity and high cholesterol drives sales.
What was the Market Share of the United States in 2022?
The United States expanded at a CAGR of 32.4% in 2022.
How North America is Likley to Offer Lucrative Growth Opportunities?
The high prevalence of cardiovascular diseases and atherosclerosis in North America offers growth opportunities.
What is India’s Market Outlook?
India expanded at a CAGR of 4.4% in 2022.
Table of Content
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Therapy
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Therapy, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Therapy, 2023 to 2033
5.3.1. Atherosclerosis Medications
5.3.2. Cholesterol-lowering Medications
5.3.3. Antiplatelet drugs and Anticoagulants
5.3.4. Atherosclerosis Beta Blockers
5.3.5. Diuretics or Water Pills
5.3.6. Angiotensin Converting Enzyme (Ace) Inhibitors
5.3.7. Others
5.4. Y-o-Y Growth Trend Analysis By Therapy, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Therapy, 2023 to 2033
6. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Surgery
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Surgery, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Surgery, 2023 to 2033
6.3.1. Bypass Surgery (Coronary Artery Bypass Grafting (CABG))
6.3.2. Angioplasty
6.3.3. Atherectomy
6.4. Y-o-Y Growth Trend Analysis By Surgery, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Surgery, 2023 to 2033
7. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel , 2018 to 2022
7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel , 2023 to 2033
7.3.1. Hospitals
7.3.2. Pharmacies
7.3.3. Drug Stores
7.3.4. Retail Pharmacies
7.3.5. Clinics
7.4. Y-o-Y Growth Trend Analysis By Distribution Channel , 2018 to 2022
7.5. Absolute $ Opportunity Analysis By Distribution Channel , 2023 to 2033
8. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
8.1. Introduction
8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
8.3.1. North America
8.3.2. Latin America
8.3.3. Western Europe
8.3.4. Eastern Europe
8.3.5. South Asia and Pacific
8.3.6. East Asia
8.3.7. Middle East and Africa
8.4. Market Attractiveness Analysis By Region
9. North America Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. U.S.
9.2.1.2. Canada
9.2.2. By Therapy
9.2.3. By Surgery
9.2.4. By Distribution Channel
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Therapy
9.3.3. By Surgery
9.3.4. By Distribution Channel
9.4. Key Takeaways
10. Latin America Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Brazil
10.2.1.2. Mexico
10.2.1.3. Rest of Latin America
10.2.2. By Therapy
10.2.3. By Surgery
10.2.4. By Distribution Channel
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Therapy
10.3.3. By Surgery
10.3.4. By Distribution Channel
10.4. Key Takeaways
11. Western Europe Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. Germany
11.2.1.2. U.K.
11.2.1.3. France
11.2.1.4. Spain
11.2.1.5. Italy
11.2.1.6. Rest of Western Europe
11.2.2. By Therapy
11.2.3. By Surgery
11.2.4. By Distribution Channel
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Therapy
11.3.3. By Surgery
11.3.4. By Distribution Channel
11.4. Key Takeaways
12. Eastern Europe Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. Poland
12.2.1.2. Russia
12.2.1.3. Czech Republic
12.2.1.4. Romania
12.2.1.5. Rest of Eastern Europe
12.2.2. By Therapy
12.2.3. By Surgery
12.2.4. By Distribution Channel
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Therapy
12.3.3. By Surgery
12.3.4. By Distribution Channel
12.4. Key Takeaways
13. South Asia and Pacific Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. India
13.2.1.2. Bangladesh
13.2.1.3. Australia
13.2.1.4. New Zealand
13.2.1.5. Rest of South Asia and Pacific
13.2.2. By Therapy
13.2.3. By Surgery
13.2.4. By Distribution Channel
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Therapy
13.3.3. By Surgery
13.3.4. By Distribution Channel
13.4. Key Takeaways
14. East Asia Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.1.1. China
14.2.1.2. Japan
14.2.1.3. South Korea
14.2.2. By Therapy
14.2.3. By Surgery
14.2.4. By Distribution Channel
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Therapy
14.3.3. By Surgery
14.3.4. By Distribution Channel
14.4. Key Takeaways
15. Middle East and Africa Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
15.2.1. By Country
15.2.1.1. GCC Countries
15.2.1.2. South Africa
15.2.1.3. Israel
15.2.1.4. Rest of MEA
15.2.2. By Therapy
15.2.3. By Surgery
15.2.4. By Distribution Channel
15.3. Market Attractiveness Analysis
15.3.1. By Country
15.3.2. By Therapy
15.3.3. By Surgery
15.3.4. By Distribution Channel
15.4. Key Takeaways
16. Key Countries Analysis
16.1. U.S.
16.1.1. Pricing Analysis
16.1.2. Market Share Analysis, 2022
16.1.2.1. By Therapy
16.1.2.2. By Surgery
16.1.2.3. By Distribution Channel
16.2. Canada
16.2.1. Pricing Analysis
16.2.2. Market Share Analysis, 2022
16.2.2.1. By Therapy
16.2.2.2. By Surgery
16.2.2.3. By Distribution Channel
16.3. Brazil
16.3.1. Pricing Analysis
16.3.2. Market Share Analysis, 2022
16.3.2.1. By Therapy
16.3.2.2. By Surgery
16.3.2.3. By Distribution Channel
16.4. Mexico
16.4.1. Pricing Analysis
16.4.2. Market Share Analysis, 2022
16.4.2.1. By Therapy
16.4.2.2. By Surgery
16.4.2.3. By Distribution Channel
16.5. Germany
16.5.1. Pricing Analysis
16.5.2. Market Share Analysis, 2022
16.5.2.1. By Therapy
16.5.2.2. By Surgery
16.5.2.3. By Distribution Channel
16.6. U.K.
16.6.1. Pricing Analysis
16.6.2. Market Share Analysis, 2022
16.6.2.1. By Therapy
16.6.2.2. By Surgery
16.6.2.3. By Distribution Channel
16.7. France
16.7.1. Pricing Analysis
16.7.2. Market Share Analysis, 2022
16.7.2.1. By Therapy
16.7.2.2. By Surgery
16.7.2.3. By Distribution Channel
16.8. Spain
16.8.1. Pricing Analysis
16.8.2. Market Share Analysis, 2022
16.8.2.1. By Therapy
16.8.2.2. By Surgery
16.8.2.3. By Distribution Channel
16.9. Italy
16.9.1. Pricing Analysis
16.9.2. Market Share Analysis, 2022
16.9.2.1. By Therapy
16.9.2.2. By Surgery
16.9.2.3. By Distribution Channel
16.10. Poland
16.10.1. Pricing Analysis
16.10.2. Market Share Analysis, 2022
16.10.2.1. By Therapy
16.10.2.2. By Surgery
16.10.2.3. By Distribution Channel
16.11. Russia
16.11.1. Pricing Analysis
16.11.2. Market Share Analysis, 2022
16.11.2.1. By Therapy
16.11.2.2. By Surgery
16.11.2.3. By Distribution Channel
16.12. Czech Republic
16.12.1. Pricing Analysis
16.12.2. Market Share Analysis, 2022
16.12.2.1. By Therapy
16.12.2.2. By Surgery
16.12.2.3. By Distribution Channel
16.13. Romania
16.13.1. Pricing Analysis
16.13.2. Market Share Analysis, 2022
16.13.2.1. By Therapy
16.13.2.2. By Surgery
16.13.2.3. By Distribution Channel
16.14. India
16.14.1. Pricing Analysis
16.14.2. Market Share Analysis, 2022
16.14.2.1. By Therapy
16.14.2.2. By Surgery
16.14.2.3. By Distribution Channel
16.15. Bangladesh
16.15.1. Pricing Analysis
16.15.2. Market Share Analysis, 2022
16.15.2.1. By Therapy
16.15.2.2. By Surgery
16.15.2.3. By Distribution Channel
16.16. Australia
16.16.1. Pricing Analysis
16.16.2. Market Share Analysis, 2022
16.16.2.1. By Therapy
16.16.2.2. By Surgery
16.16.2.3. By Distribution Channel
16.17. New Zealand
16.17.1. Pricing Analysis
16.17.2. Market Share Analysis, 2022
16.17.2.1. By Therapy
16.17.2.2. By Surgery
16.17.2.3. By Distribution Channel
16.18. China
16.18.1. Pricing Analysis
16.18.2. Market Share Analysis, 2022
16.18.2.1. By Therapy
16.18.2.2. By Surgery
16.18.2.3. By Distribution Channel
16.19. Japan
16.19.1. Pricing Analysis
16.19.2. Market Share Analysis, 2022
16.19.2.1. By Therapy
16.19.2.2. By Surgery
16.19.2.3. By Distribution Channel
16.20. South Korea
16.20.1. Pricing Analysis
16.20.2. Market Share Analysis, 2022
16.20.2.1. By Therapy
16.20.2.2. By Surgery
16.20.2.3. By Distribution Channel
16.21. GCC Countries
16.21.1. Pricing Analysis
16.21.2. Market Share Analysis, 2022
16.21.2.1. By Therapy
16.21.2.2. By Surgery
16.21.2.3. By Distribution Channel
16.22. South Africa
16.22.1. Pricing Analysis
16.22.2. Market Share Analysis, 2022
16.22.2.1. By Therapy
16.22.2.2. By Surgery
16.22.2.3. By Distribution Channel
16.23. Israel
16.23.1. Pricing Analysis
16.23.2. Market Share Analysis, 2022
16.23.2.1. By Therapy
16.23.2.2. By Surgery
16.23.2.3. By Distribution Channel
17. Market Structure Analysis
17.1. Competition Dashboard
17.2. Competition Benchmarking
17.3. Market Share Analysis of Top Players
17.3.1. By Regional
17.3.2. By Therapy
17.3.3. By Surgery
17.3.4. By Distribution Channel
18. Competition Analysis
18.1. Competition Deep Dive
18.1.1. GlaxoSmithKline plc.
18.1.1.1. Overview
18.1.1.2. Product Portfolio
18.1.1.3. Profitability by Market Segments
18.1.1.4. Sales Footprint
18.1.1.5. Strategy Overview
18.1.1.5.1. Marketing Strategy
18.1.2. Merck & Co., Inc.
18.1.2.1. Overview
18.1.2.2. Product Portfolio
18.1.2.3. Profitability by Market Segments
18.1.2.4. Sales Footprint
18.1.2.5. Strategy Overview
18.1.2.5.1. Marketing Strategy
18.1.3. F. Hoffmann-La Roche Ltd.
18.1.3.1. Overview
18.1.3.2. Product Portfolio
18.1.3.3. Profitability by Market Segments
18.1.3.4. Sales Footprint
18.1.3.5. Strategy Overview
18.1.3.5.1. Marketing Strategy
18.1.4. Isis Pharmaceuticals, Inc.
18.1.4.1. Overview
18.1.4.2. Product Portfolio
18.1.4.3. Profitability by Market Segments
18.1.4.4. Sales Footprint
18.1.4.5. Strategy Overview
18.1.4.5.1. Marketing Strategy
18.1.5. Anthera Pharmaceuticals
18.1.5.1. Overview
18.1.5.2. Product Portfolio
18.1.5.3. Profitability by Market Segments
18.1.5.4. Sales Footprint
18.1.5.5. Strategy Overview
18.1.5.5.1. Marketing Strategy
18.1.6. Novartis AG
18.1.6.1. Overview
18.1.6.2. Product Portfolio
18.1.6.3. Profitability by Market Segments
18.1.6.4. Sales Footprint
18.1.6.5. Strategy Overview
18.1.6.5.1. Marketing Strategy
18.1.7. Sanofi
18.1.7.1. Overview
18.1.7.2. Product Portfolio
18.1.7.3. Profitability by Market Segments
18.1.7.4. Sales Footprint
18.1.7.5. Strategy Overview
18.1.7.5.1. Marketing Strategy
18.1.8. Johnson and Johnson
18.1.8.1. Overview
18.1.8.2. Product Portfolio
18.1.8.3. Profitability by Market Segments
18.1.8.4. Sales Footprint
18.1.8.5. Strategy Overview
18.1.8.5.1. Marketing Strategy
18.1.9. Bayer AG
18.1.9.1. Overview
18.1.9.2. Product Portfolio
18.1.9.3. Profitability by Market Segments
18.1.9.4. Sales Footprint
18.1.9.5. Strategy Overview
18.1.9.5.1. Marketing Strategy
18.1.10. The Medicine Company
18.1.10.1. Overview
18.1.10.2. Product Portfolio
18.1.10.3. Profitability by Market Segments
18.1.10.4. Sales Footprint
18.1.10.5. Strategy Overview
18.1.10.5.1. Marketing Strategy
18.1.11. Cardium Therapeutics
18.1.11.1. Overview
18.1.11.2. Product Portfolio
18.1.11.3. Profitability by Market Segments
18.1.11.4. Sales Footprint
18.1.11.5. Strategy Overview
18.1.11.5.1. Marketing Strategy
19. Assumptions & Acronyms Used20. Research Methodology
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
List of Tables
Table 1: Global Value (US$ Million) Forecast by Region, 2018 to 2033
Table 2: Global Value (US$ Million) Forecast by Therapy, 2018 to 2033
Table 3: Global Value (US$ Million) Forecast by Surgery, 2018 to 2033
Table 4: Global Value (US$ Million) Forecast by Distribution Channel , 2018 to 2033
Table 5: North America Value (US$ Million) Forecast by Country, 2018 to 2033
Table 6: North America Value (US$ Million) Forecast by Therapy, 2018 to 2033
Table 7: North America Value (US$ Million) Forecast by Surgery, 2018 to 2033
Table 8: North America Value (US$ Million) Forecast by Distribution Channel , 2018 to 2033
Table 9: Latin America Value (US$ Million) Forecast by Country, 2018 to 2033
Table 10: Latin America Value (US$ Million) Forecast by Therapy, 2018 to 2033
Table 11: Latin America Value (US$ Million) Forecast by Surgery, 2018 to 2033
Table 12: Latin America Value (US$ Million) Forecast by Distribution Channel , 2018 to 2033
Table 13: Western Europe Value (US$ Million) Forecast by Country, 2018 to 2033
Table 14: Western Europe Value (US$ Million) Forecast by Therapy, 2018 to 2033
Table 15: Western Europe Value (US$ Million) Forecast by Surgery, 2018 to 2033
Table 16: Western Europe Value (US$ Million) Forecast by Distribution Channel , 2018 to 2033
Table 17: Eastern Europe Value (US$ Million) Forecast by Country, 2018 to 2033
Table 18: Eastern Europe Value (US$ Million) Forecast by Therapy, 2018 to 2033
Table 19: Eastern Europe Value (US$ Million) Forecast by Surgery, 2018 to 2033
Table 20: Eastern Europe Value (US$ Million) Forecast by Distribution Channel , 2018 to 2033
Table 21: South Asia and Pacific Value (US$ Million) Forecast by Country, 2018 to 2033
Table 22: South Asia and Pacific Value (US$ Million) Forecast by Therapy, 2018 to 2033
Table 23: South Asia and Pacific Value (US$ Million) Forecast by Surgery, 2018 to 2033
Table 24: South Asia and Pacific Value (US$ Million) Forecast by Distribution Channel , 2018 to 2033
Table 25: East Asia Value (US$ Million) Forecast by Country, 2018 to 2033
Table 26: East Asia Value (US$ Million) Forecast by Therapy, 2018 to 2033
Table 27: East Asia Value (US$ Million) Forecast by Surgery, 2018 to 2033
Table 28: East Asia Value (US$ Million) Forecast by Distribution Channel , 2018 to 2033
Table 29: Middle East and Africa Value (US$ Million) Forecast by Country, 2018 to 2033
Table 30: Middle East and Africa Value (US$ Million) Forecast by Therapy, 2018 to 2033
Table 31: Middle East and Africa Value (US$ Million) Forecast by Surgery, 2018 to 2033
Table 32: Middle East and Africa Value (US$ Million) Forecast by Distribution Channel , 2018 to 2033
Find your sweet spots for generating winning opportunities in this market.
List of Charts
Figure 1: Global Value (US$ Million) by Therapy, 2023 to 2033
Figure 2: Global Value (US$ Million) by Surgery, 2023 to 2033
Figure 3: Global Value (US$ Million) by Distribution Channel , 2023 to 2033
Figure 4: Global Value (US$ Million) by Region, 2023 to 2033
Figure 5: Global Value (US$ Million) Analysis by Region, 2018 to 2033
Figure 6: Global Value Share (%) and BPS Analysis by Region, 2023 to 2033
Figure 7: Global Y-o-Y Growth (%) Projections by Region, 2023 to 2033
Figure 8: Global Value (US$ Million) Analysis by Therapy, 2018 to 2033
Figure 9: Global Value Share (%) and BPS Analysis by Therapy, 2023 to 2033
Figure 10: Global Y-o-Y Growth (%) Projections by Therapy, 2023 to 2033
Figure 11: Global Value (US$ Million) Analysis by Surgery, 2018 to 2033
Figure 12: Global Value Share (%) and BPS Analysis by Surgery, 2023 to 2033
Figure 13: Global Y-o-Y Growth (%) Projections by Surgery, 2023 to 2033
Figure 14: Global Value (US$ Million) Analysis by Distribution Channel , 2018 to 2033
Figure 15: Global Value Share (%) and BPS Analysis by Distribution Channel , 2023 to 2033
Figure 16: Global Y-o-Y Growth (%) Projections by Distribution Channel , 2023 to 2033
Figure 17: Global Attractiveness by Therapy, 2023 to 2033
Figure 18: Global Attractiveness by Surgery, 2023 to 2033
Figure 19: Global Attractiveness by Distribution Channel , 2023 to 2033
Figure 20: Global Attractiveness by Region, 2023 to 2033
Figure 21: North America Value (US$ Million) by Therapy, 2023 to 2033
Figure 22: North America Value (US$ Million) by Surgery, 2023 to 2033
Figure 23: North America Value (US$ Million) by Distribution Channel , 2023 to 2033
Figure 24: North America Value (US$ Million) by Country, 2023 to 2033
Figure 25: North America Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 26: North America Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 27: North America Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 28: North America Value (US$ Million) Analysis by Therapy, 2018 to 2033
Figure 29: North America Value Share (%) and BPS Analysis by Therapy, 2023 to 2033
Figure 30: North America Y-o-Y Growth (%) Projections by Therapy, 2023 to 2033
Figure 31: North America Value (US$ Million) Analysis by Surgery, 2018 to 2033
Figure 32: North America Value Share (%) and BPS Analysis by Surgery, 2023 to 2033
Figure 33: North America Y-o-Y Growth (%) Projections by Surgery, 2023 to 2033
Figure 34: North America Value (US$ Million) Analysis by Distribution Channel , 2018 to 2033
Figure 35: North America Value Share (%) and BPS Analysis by Distribution Channel , 2023 to 2033
Figure 36: North America Y-o-Y Growth (%) Projections by Distribution Channel , 2023 to 2033
Figure 37: North America Attractiveness by Therapy, 2023 to 2033
Figure 38: North America Attractiveness by Surgery, 2023 to 2033
Figure 39: North America Attractiveness by Distribution Channel , 2023 to 2033
Figure 40: North America Attractiveness by Country, 2023 to 2033
Figure 41: Latin America Value (US$ Million) by Therapy, 2023 to 2033
Figure 42: Latin America Value (US$ Million) by Surgery, 2023 to 2033
Figure 43: Latin America Value (US$ Million) by Distribution Channel , 2023 to 2033
Figure 44: Latin America Value (US$ Million) by Country, 2023 to 2033
Figure 45: Latin America Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 46: Latin America Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 47: Latin America Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 48: Latin America Value (US$ Million) Analysis by Therapy, 2018 to 2033
Figure 49: Latin America Value Share (%) and BPS Analysis by Therapy, 2023 to 2033
Figure 50: Latin America Y-o-Y Growth (%) Projections by Therapy, 2023 to 2033
Figure 51: Latin America Value (US$ Million) Analysis by Surgery, 2018 to 2033
Figure 52: Latin America Value Share (%) and BPS Analysis by Surgery, 2023 to 2033
Figure 53: Latin America Y-o-Y Growth (%) Projections by Surgery, 2023 to 2033
Figure 54: Latin America Value (US$ Million) Analysis by Distribution Channel , 2018 to 2033
Figure 55: Latin America Value Share (%) and BPS Analysis by Distribution Channel , 2023 to 2033
Figure 56: Latin America Y-o-Y Growth (%) Projections by Distribution Channel , 2023 to 2033
Figure 57: Latin America Attractiveness by Therapy, 2023 to 2033
Figure 58: Latin America Attractiveness by Surgery, 2023 to 2033
Figure 59: Latin America Attractiveness by Distribution Channel , 2023 to 2033
Figure 60: Latin America Attractiveness by Country, 2023 to 2033
Figure 61: Western Europe Value (US$ Million) by Therapy, 2023 to 2033
Figure 62: Western Europe Value (US$ Million) by Surgery, 2023 to 2033
Figure 63: Western Europe Value (US$ Million) by Distribution Channel , 2023 to 2033
Figure 64: Western Europe Value (US$ Million) by Country, 2023 to 2033
Figure 65: Western Europe Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 66: Western Europe Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 67: Western Europe Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 68: Western Europe Value (US$ Million) Analysis by Therapy, 2018 to 2033
Figure 69: Western Europe Value Share (%) and BPS Analysis by Therapy, 2023 to 2033
Figure 70: Western Europe Y-o-Y Growth (%) Projections by Therapy, 2023 to 2033
Figure 71: Western Europe Value (US$ Million) Analysis by Surgery, 2018 to 2033
Figure 72: Western Europe Value Share (%) and BPS Analysis by Surgery, 2023 to 2033
Figure 73: Western Europe Y-o-Y Growth (%) Projections by Surgery, 2023 to 2033
Figure 74: Western Europe Value (US$ Million) Analysis by Distribution Channel , 2018 to 2033
Figure 75: Western Europe Value Share (%) and BPS Analysis by Distribution Channel , 2023 to 2033
Figure 76: Western Europe Y-o-Y Growth (%) Projections by Distribution Channel , 2023 to 2033
Figure 77: Western Europe Attractiveness by Therapy, 2023 to 2033
Figure 78: Western Europe Attractiveness by Surgery, 2023 to 2033
Figure 79: Western Europe Attractiveness by Distribution Channel , 2023 to 2033
Figure 80: Western Europe Attractiveness by Country, 2023 to 2033
Figure 81: Eastern Europe Value (US$ Million) by Therapy, 2023 to 2033
Figure 82: Eastern Europe Value (US$ Million) by Surgery, 2023 to 2033
Figure 83: Eastern Europe Value (US$ Million) by Distribution Channel , 2023 to 2033
Figure 84: Eastern Europe Value (US$ Million) by Country, 2023 to 2033
Figure 85: Eastern Europe Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 86: Eastern Europe Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 87: Eastern Europe Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 88: Eastern Europe Value (US$ Million) Analysis by Therapy, 2018 to 2033
Figure 89: Eastern Europe Value Share (%) and BPS Analysis by Therapy, 2023 to 2033
Figure 90: Eastern Europe Y-o-Y Growth (%) Projections by Therapy, 2023 to 2033
Figure 91: Eastern Europe Value (US$ Million) Analysis by Surgery, 2018 to 2033
Figure 92: Eastern Europe Value Share (%) and BPS Analysis by Surgery, 2023 to 2033
Figure 93: Eastern Europe Y-o-Y Growth (%) Projections by Surgery, 2023 to 2033
Figure 94: Eastern Europe Value (US$ Million) Analysis by Distribution Channel , 2018 to 2033
Figure 95: Eastern Europe Value Share (%) and BPS Analysis by Distribution Channel , 2023 to 2033
Figure 96: Eastern Europe Y-o-Y Growth (%) Projections by Distribution Channel , 2023 to 2033
Figure 97: Eastern Europe Attractiveness by Therapy, 2023 to 2033
Figure 98: Eastern Europe Attractiveness by Surgery, 2023 to 2033
Figure 99: Eastern Europe Attractiveness by Distribution Channel , 2023 to 2033
Figure 100: Eastern Europe Attractiveness by Country, 2023 to 2033
Figure 101: South Asia and Pacific Value (US$ Million) by Therapy, 2023 to 2033
Figure 102: South Asia and Pacific Value (US$ Million) by Surgery, 2023 to 2033
Figure 103: South Asia and Pacific Value (US$ Million) by Distribution Channel , 2023 to 2033
Figure 104: South Asia and Pacific Value (US$ Million) by Country, 2023 to 2033
Figure 105: South Asia and Pacific Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 106: South Asia and Pacific Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 107: South Asia and Pacific Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 108: South Asia and Pacific Value (US$ Million) Analysis by Therapy, 2018 to 2033
Figure 109: South Asia and Pacific Value Share (%) and BPS Analysis by Therapy, 2023 to 2033
Figure 110: South Asia and Pacific Y-o-Y Growth (%) Projections by Therapy, 2023 to 2033
Figure 111: South Asia and Pacific Value (US$ Million) Analysis by Surgery, 2018 to 2033
Figure 112: South Asia and Pacific Value Share (%) and BPS Analysis by Surgery, 2023 to 2033
Figure 113: South Asia and Pacific Y-o-Y Growth (%) Projections by Surgery, 2023 to 2033
Figure 114: South Asia and Pacific Value (US$ Million) Analysis by Distribution Channel , 2018 to 2033
Figure 115: South Asia and Pacific Value Share (%) and BPS Analysis by Distribution Channel , 2023 to 2033
Figure 116: South Asia and Pacific Y-o-Y Growth (%) Projections by Distribution Channel , 2023 to 2033
Figure 117: South Asia and Pacific Attractiveness by Therapy, 2023 to 2033
Figure 118: South Asia and Pacific Attractiveness by Surgery, 2023 to 2033
Figure 119: South Asia and Pacific Attractiveness by Distribution Channel , 2023 to 2033
Figure 120: South Asia and Pacific Attractiveness by Country, 2023 to 2033
Figure 121: East Asia Value (US$ Million) by Therapy, 2023 to 2033
Figure 122: East Asia Value (US$ Million) by Surgery, 2023 to 2033
Figure 123: East Asia Value (US$ Million) by Distribution Channel , 2023 to 2033
Figure 124: East Asia Value (US$ Million) by Country, 2023 to 2033
Figure 125: East Asia Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 126: East Asia Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 127: East Asia Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 128: East Asia Value (US$ Million) Analysis by Therapy, 2018 to 2033
Figure 129: East Asia Value Share (%) and BPS Analysis by Therapy, 2023 to 2033
Figure 130: East Asia Y-o-Y Growth (%) Projections by Therapy, 2023 to 2033
Figure 131: East Asia Value (US$ Million) Analysis by Surgery, 2018 to 2033
Figure 132: East Asia Value Share (%) and BPS Analysis by Surgery, 2023 to 2033
Figure 133: East Asia Y-o-Y Growth (%) Projections by Surgery, 2023 to 2033
Figure 134: East Asia Value (US$ Million) Analysis by Distribution Channel , 2018 to 2033
Figure 135: East Asia Value Share (%) and BPS Analysis by Distribution Channel , 2023 to 2033
Figure 136: East Asia Y-o-Y Growth (%) Projections by Distribution Channel , 2023 to 2033
Figure 137: East Asia Attractiveness by Therapy, 2023 to 2033
Figure 138: East Asia Attractiveness by Surgery, 2023 to 2033
Figure 139: East Asia Attractiveness by Distribution Channel , 2023 to 2033
Figure 140: East Asia Attractiveness by Country, 2023 to 2033
Figure 141: Middle East and Africa Value (US$ Million) by Therapy, 2023 to 2033
Figure 142: Middle East and Africa Value (US$ Million) by Surgery, 2023 to 2033
Figure 143: Middle East and Africa Value (US$ Million) by Distribution Channel , 2023 to 2033
Figure 144: Middle East and Africa Value (US$ Million) by Country, 2023 to 2033
Figure 145: Middle East and Africa Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 146: Middle East and Africa Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 147: Middle East and Africa Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 148: Middle East and Africa Value (US$ Million) Analysis by Therapy, 2018 to 2033
Figure 149: Middle East and Africa Value Share (%) and BPS Analysis by Therapy, 2023 to 2033
Figure 150: Middle East and Africa Y-o-Y Growth (%) Projections by Therapy, 2023 to 2033
Figure 151: Middle East and Africa Value (US$ Million) Analysis by Surgery, 2018 to 2033
Figure 152: Middle East and Africa Value Share (%) and BPS Analysis by Surgery, 2023 to 2033
Figure 153: Middle East and Africa Y-o-Y Growth (%) Projections by Surgery, 2023 to 2033
Figure 154: Middle East and Africa Value (US$ Million) Analysis by Distribution Channel , 2018 to 2033
Figure 155: Middle East and Africa Value Share (%) and BPS Analysis by Distribution Channel , 2023 to 2033
Figure 156: Middle East and Africa Y-o-Y Growth (%) Projections by Distribution Channel , 2023 to 2033
Figure 157: Middle East and Africa Attractiveness by Therapy, 2023 to 2033
Figure 158: Middle East and Africa Attractiveness by Surgery, 2023 to 2033
Figure 159: Middle East and Africa Attractiveness by Distribution Channel , 2023 to 2033
Figure 160: Middle East and Africa Attractiveness by Country, 2023 to 2033
